MaRS Innovation to commercialize two technologies

Guest Contributor
July 8, 2009

MaRS Innovation has announced its first two medical technologies for commercialization. MaRS Innovation — funded through the Centres of Excellence for Commercialization and Research program (R$, October 7/08) — is collaborating with the Samuel Lunenfeld Research Institute (SLRI) to commercialize an umbilical cord stem cell technology to initially treat diabetes and possible cardiovascular disease and neurological disorders The technology was developed by SLRI scientists Dr Ian Rogers and Dr Robert Casper. The second initiative is with the Univ of Toronto to commercialize sustained release formulation of nitric oxide (NO) for applications in wound healing, including diabetic ulcers. U of T scientists Dr Ping lee and Dr Yan Li developed the NO sustained release technology….

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.